NasdaqGS - Nasdaq Real Time Price USD
Taysha Gene Therapies, Inc. (TSHA)
At close: November 5 at 4:00 PM EST
After hours: 7:50 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
12,873.0000
15,451.0000
2,502.0000
--
--
Operating Expense
89,933.0000
86,825.0000
128,529.0000
173,267.0000
43,002.0000
Operating Income
-77,060.0000
-71,374.0000
-126,027.0000
-173,267.0000
-43,002.0000
Net Non Operating Interest Income Expense
3,923.0000
-1,426.0000
-3,549.0000
-1,256.0000
21.0000
Other Income Expense
-41,198.0000
-38,766.0000
-36,438.0000
--
-17,030.0000
Pretax Income
-114,335.0000
-111,566.0000
-166,014.0000
-174,523.0000
-60,011.0000
Net Income Common Stockholders
-114,335.0000
-111,566.0000
-166,014.0000
-174,523.0000
-60,011.0000
Diluted NI Available to Com Stockholders
-114,335.0000
-111,566.0000
-166,014.0000
-174,523.0000
-60,011.0000
Basic EPS
-0.49
-0.96
-3.78
-4.64
-3.40
Diluted EPS
-0.49
-0.96
-3.78
-4.64
-3.40
Basic Average Shares
200,261.4880
116,121.4820
43,952.0150
37,650.5660
17,665.6830
Diluted Average Shares
200,261.4880
116,121.4820
43,952.0150
37,650.5660
17,665.6830
Total Operating Income as Reported
-78,125.0000
-72,439.0000
-162,447.0000
-173,267.0000
-43,002.0000
Total Expenses
89,933.0000
86,825.0000
128,529.0000
173,267.0000
43,002.0000
Net Income from Continuing & Discontinued Operation
-114,335.0000
-111,566.0000
-166,014.0000
-174,523.0000
-60,011.0000
Normalized Income
-77,012.0000
-74,385.0000
-129,594.0000
-174,523.0000
-60,011.0000
Interest Income
6,163.0000
3,572.0000
249.0000
172.0000
49.0000
Interest Expense
2,240.0000
4,998.0000
3,798.0000
1,428.0000
28.0000
Net Interest Income
3,923.0000
-1,426.0000
-3,549.0000
-1,256.0000
21.0000
EBIT
-112,095.0000
-106,568.0000
-162,216.0000
-173,095.0000
-59,983.0000
EBITDA
-110,751.0000
-105,197.0000
-161,044.0000
-172,603.0000
-59,974.0000
Reconciled Depreciation
1,344.0000
1,371.0000
1,172.0000
492.0000
9.0000
Net Income from Continuing Operation Net Minority Interest
-114,335.0000
-111,566.0000
-166,014.0000
-174,523.0000
-60,011.0000
Total Unusual Items Excluding Goodwill
-37,323.0000
-37,181.0000
-36,420.0000
--
--
Total Unusual Items
-37,323.0000
-37,181.0000
-36,420.0000
--
--
Normalized EBITDA
-73,428.0000
-68,016.0000
-124,624.0000
-172,603.0000
-59,974.0000
12/31/2020 - 9/24/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NGNE Neurogene Inc.
64.40
-2.42%
TYRA Tyra Biosciences, Inc.
16.76
+2.07%
ANAB AnaptysBio, Inc.
19.88
-0.30%
VRCA Verrica Pharmaceuticals Inc.
0.7975
-44.23%
ALXO ALX Oncology Holdings Inc.
1.5200
+2.01%
CCCC C4 Therapeutics, Inc.
6.09
-5.58%
RLYB Rallybio Corporation
1.0200
0.00%
PASG Passage Bio, Inc.
0.6216
+2.83%
SANA Sana Biotechnology, Inc.
3.3900
-9.84%
SPRB Spruce Biosciences, Inc.
0.5401
+0.95%